Clinical trial
Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease…
NCT03363373 · Y-mAbs Therapeutics, Industry · Recruiting
Key facts
| NCT number | NCT03363373 |
|---|---|
| Title | Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow |
| Official title | A Pivotal Phase 2 Trial of Antibody Naxitamab (hu3F8) and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow |
| Lead sponsor | Y-mAbs Therapeutics, Industry |
| Status | Recruiting |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Neuroblastoma |
| Intervention type | Biological |
| Interventions | GM-CSF + Naxitamab |
| Enrollment | 122 |
| Start date | Apr 3, 2018 |
| Primary completion | Apr 1, 2026 |
| Completion | Apr 1, 2028 |
| First posted | Dec 6, 2017 |
| Last update posted | Aug 17, 2025 |
| Countries | Canada, Denmark, France, Germany, Hong Kong, India, Italy, Spain, United Kingdom, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: